[ad_1]
SAN FRANCISCO – (BUSINESS WIRE) –Current
Health, a portable remote control with artificial intelligence (AI)
patient monitoring platform (RPM), announced today that it has received
Clearance II of the US Food and Drug Administration (FDA) for
post-acute care. Available for hospital and home, Current a
obtained the first ever FDA clearance for an end-to-end, real-time solution
Passive passive RPM and platform.
The FDA's post-acute approval is taking place right now
overwhelming customer demand for its platform, combining its all-in-one
portable wireless, which provides precision at the level of the ICU and follows more
vital signs that any other all-in-one notebook available today, with
analysis to obtain actionable information. Current is already a partner
with six of the largest health systems in the United States, including Mount
Sinai, and with several UK NHS trusts, helping them to provide
home health care earlier to reduce readmissions and avoidable deaths.
As the health sector evolves towards value-based care, providers need to
intervene earlier to improve patient outcomes, reduce length of stay
and reduce readmissions to the hospital. However, suppliers have no way of
identify patients at risk after discharge from the hospital. Traditional
RPM and telehealth solutions can not meet these challenges because of
continued confidence in manual data entry, unreliable spot measurements,
lack of widespread adoption and low patient compliance.
"Real-time monitoring of vital signs at home allows our team to
act on the first signs of declining health, avoidable preventable
hospitalizations, "said Dr Neta Faynboym, executive director of the CPE,
Innovation: Medicare Advantage / Abordability, at Banner Health.
Designed specifically for the patient, Current Passive
measures the vital signs of the patient in real time with the arm
portable. Developed using one of the largest physiological data in the world
Current's proprietary algorithms continually analyze data for
determine the health trajectory of a patient by detecting potential indicators
patient drops earlier for faster intervention.
Current FDA Approval for its RPM and Telehealth
platform, which includes Bluetooth integrations with other advanced technologies
devices for tracking metrics. Patients receive a tablet equipped with a
chatbot for questions and answers, drug reminders and educational content, which
allows patients to communicate with clinicians via a video chat or text message to
report symptoms and discuss care.
"Our fast growing clientele shows how targeted health systems
and home health agencies are on moving more health care from the hospital to
at home, "said Christopher McCann, CEO and co-founder of Current Health.
"Today, Current helps them do just that by monitoring
health care pathways to allow earlier interventions, reduce the risk of
increasing costs of hospital readmissions and, more importantly, prevention
avoidable deaths. But more fundamentally, we are building a future where
health care comes to us. Patients do not always know when to call their
doctor. Present will. "
For more information:
About current health
Current Health helps health care
Providers intervene proactively at home and at the hospital through ongoing procedures
wireless monitoring and accurate early warnings. We are watching
human body in real time. With FDA clearance and with ICU level accuracy, we
Follow more vital signs than any other all-in-one device. Today, we are
focused on helping health care providers provide earlier treatment
reduce readmissions and avoidable deaths, while strengthening
ability to predict the onset of the disease. Headquartered in Edinburgh,
Scotland, Current is a venture capital firm invested by ADV Investors, MMC Ventures and
other. For more information, visit https://www.currenthealth.com/.
Source link
